CD38-GEAR-NK

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD38-GEAR-NK
Drug Alias Nameautologous CD38 NK cell therapy (Coeptis Pharmaceuticals/VyGen Bio)CD38-GEAR-NK
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulators
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCoeptis Pharmaceuticals, Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVyGen-Bio IncCoeptis Pharmaceuticals, Inc
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A